首页> 外文期刊>Macedonian Journal of Medical Sciences >Protective Effects of Aliskiren, Enalapril and Valsartan on Hypertension Target Organs in Spontaneously Hypertensive Rats
【24h】

Protective Effects of Aliskiren, Enalapril and Valsartan on Hypertension Target Organs in Spontaneously Hypertensive Rats

机译:阿利吉仑,依那普利和缬沙坦对自发性高血压大鼠高血压靶器官的保护作用

获取原文
           

摘要

Protective Effects of Aliskiren, Enalapril and Valsartan on Hypertension Target Organs in Spontaneously Hypertensive RatsAim: Aliskiren is the first orally active renin inhibitor approved for treatment of essential hypertension. There are as yet no clinical data regarding the ability of aliskiren to prevent clinical end-points or reduce end-organ damage over and above the presumed effects of blood pressure reduction. The aim of this study was to find out if aliskiren has a potential to improve renal function and if it has a protective effect on hypertension target organs (kidney, heart and aorta).Materials and Methods: The study was conducted on 64 SHR rats (male and female), 20 weeks old, weighing from 250-300 g. Animals were divided into 4 groups and treated with aliskiren (100 mg/kg bw/24 h), enalapril (10 mg/kg bw/24 h) and valsartan (10 mg/kg bw/24 h). Effects of investigated drugs were evaluated by urinalysis and histopathological analysis.Results: Diuresis was significantly increased in the group of animals treated with enalapril and valsartan. Effect on diuresis with aliskiren was mild and statistically insignificant. No significant difference in urine pH between treated and control group of SHR rats was noted. Albuminuria was decreased in animals treated with enalapril and valsartan. Aliskiren after 28 days of treatment had a statistically insignificant effect on albuminuria in SHR rats. Only certain changes of wall thickness of arteries and arterioles were noted that led to improved perfusion and function of the kidneys more pronounced in rats treated with valsartan and enalapril. Effects of aliskiren on target organs were inferior compared to valsartan and enalapril.Conclusion: In SHR experimental model aliskiren has minor effects on hypertension target organs when compared to enalapril and valsaratan.
机译:阿利吉仑,依那普利和缬沙坦对自发性高血压大鼠高血压靶器官的保护作用目的:阿利吉仑是第一种被批准用于治疗原发性高血压的口服活性肾素抑制剂。尚无关于阿利吉仑预防临床终点或减轻血压降低的预期效应的临床终点或减少终末器官损害的能力的临床数据。这项研究的目的是确定阿利吉仑是否具有改善肾脏功能的潜力,以及它是否对高血压的靶器官(肾脏,心脏和主动脉)具有保护作用。男性和女性),20周龄,体重250-300克。将动物分为4组,并用阿利吉仑(100mg / kg bw / 24h),依那普利(10mg / kg bw / 24h)和缬沙坦(10mg / kg bw / 24h)治疗。结果:通过依那普利和缬沙坦治疗的动物,利尿作用明显增加。阿利吉仑对利尿的影响是轻微的,在统计学上不显着。 SHR大鼠的治疗组和对照组之间的尿液pH值没有显着差异。用依那普利和缬沙坦治疗的动物蛋白尿减少。治疗28天后,阿利吉仑对SHR大鼠白蛋白尿的影响无统计学意义。仅观察到动脉和小动脉壁厚的某些变化,这导致在用缬沙坦和依那普利治疗的大鼠中肾脏的灌注和功能改善更为明显。结论:在SHR实验模型中,阿利吉仑对高血压靶器官的影响较依那普利和缬沙坦少,对缬沙坦和依那普利的影响较差。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号